mail2

Protect

Against Relapses

Reduce Risk of Relapse or Stop them Quickly if They Occur

Approved therapeutics for NMOSD have been demonstrated to be safe and effective in significantly reducing risks of future relapses, and may reduce the severity of a relapse if it occurs. While current treatment strategies for relapse can be helpful (e.g. steroids, PLEX and/or IVIG), steroids are slow to halt ongoing disease lesions and PLEX or IVIG do not halt immune cell drivers of relapses. GJCF and research partners are exploring new ways to quickly stop relapses.

Current treatments for relapses are helpful, but there is room to improve speed, specificity & tolerability of relapse therapy.

Limitations of Current Relapse Therapies

Picture1

INTRAVENOUS
STEROIDS
 

  • Broad Immune Suppression
  • Relatively Slow Effect Time
  • Side Effects Are Non-Trivial
Plasma Exchange

PLASMA
EXCHANGE
(PLEX)

  • Removes Molecules Not Cells
  • May Remove Good Factor(s)
  • Requires Extensive IV Access
Picture1

INTRAVENOUS
IMMUNOGLOBULIN
(IVIg)

  • Non-Specific Mode of Action
  • May Inhibit Good Factor(s)
  • Potential Infusion Reactions

GJCF is working with industry on new ways to more quickly treat relapses to stop CNS damage and avoid any harmful side effects.

Features of Improved Relapse Therapies

Picture1

  • At-the-Ready & Fast-Acting

  • Oral Tablet or Simple Injection

  • Portability for Use Anywhere

Picture2

  • Targets Harmful Effects of Relapse

  • Short-Acting for Optimal Control

  • Small Molecule BBB Accessibility

Picture3

  • Safe & Effective in Clinical Trials

  • Minimal Side Effects / Infections

  • Addresses NMOSD and MOGAD

Next: PIONEER

Restore Immune Tolerance to Cure NMOSD & Like Diseases

Approved therapies are a great first step toward preventing relapses. GJCF is now pioneering bold new approaches to cure NMOSD once and for all.